PATENT CLAIM ANALYSIS

Application Number: 16000467
Application Type: Utility
Filing Date: 2018-06
Publication Date: 2018-10
Patent Classification: ["514", "282000"]

Abstract:
The invention relates to novel strategies for the treatment of cancer patients based on a combination of an opioid receptor agonist and an anticancer compound.

Claim (Index 32):
The method according to  claim 33 , wherein the patient exhibits one or more of the subsequent resistances:\n i. apoptosis resistance; ii. multi-drug resistance; iii. anticancer drug resistance; iv. cytotoxic drug resistance; v. resistance to reactive oxygen species; vi. resistance to DNA damaging agents; vii. resistance to toxic antibodies; viii. doxorubicin or rituximab resistance; ix. cisplatin resistance; x. temozolomide resistance; xi. resistance to HER2 targeting therapy, selected from the group consisting of trastuzumab treatment xii. single or cross resistance to one or more of the following drug substances: methotrexate, cytarabine, cisplatine, etoposide, vincristine, paclitaxel, carboplatin, cisplatin, oxaliplatin, gemcitabine, temozolomide, thioguanine, teniposide, dexamethasone, prednisolone, cyclophosphamide, diphosphamide, doxorubicin, epirubicin, idarubicin, daunorubicin, mercaptopurine and fludarabine; and xiii. Irradiation resistance.

Metadata:
- Claim Count in Document: 59.0
- Percentile: 94.0
- Lexical Diversity: 1.08333
- Patent Class: 514.0
- Transitional Phrase Type: closed
- Component Type: 1
- Foreign Priority: True
- Related Applications: ['10835511', '13338809', '15920486', '13907035', '14427426']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8003645444262983
- 35 USC 102 Novelty (BERT): 0.5200227067501891
- Combined Prediction Score: 0.7723303606586874
- Mean Citation Score: 292.329026
- Max Citation Score: 308.32446
- Similarity Product: 195.59310143063303

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test